Martin Edelman, ASCO 2018 – Dinutuximab and irinotecan as a treatment option for small cell lung cancer
Martin Edelman from the Fox Chase Cancer Center in Philadelphia, PA, US discusses current treatments and unmet needs in small cell lung cancer and how research into immunotherapy, including dinutuximab and irinotecan as a second-line therapy, can contribute to treatment strategies.
1. What are the most important unmet needs in the treatment of small cell lung cancer (SCLC)? (0:11)
2. What options are available for patients who relapse or are refractory to first-line treatment? (0:38)
3. What factors impact the efficacy of and outcome after second-line treatments for SCLC? (1:29)
4. Could you tell us a little about the recent phase II/III study of dinutuximab and irinotecan for second-line treatment of SCLC? (1:56)
5. What advances have been made in the second-line therapy of SCLC using immunotherapy? (2:45)
Speaker disclosures: Martin Edelman has provided consultancy for Precision Oncology.
Filmed at the American Society of Clinical Oncology (ASCO) Annual Meeting 2018, Chicago, IL, US, June 1–5 2018
Share this Video
Related Videos In Lung Cancer
Sunil Singhal, AACR 2023: Intraoperative molecular imaging as a tool in cancer surgery
Intraoperative molecular imaging enables surgeons to utilise a cancer specific fluorescent dye to improve cancer removal. In this touchONCOLOGY interview, we speak with Dr Sunil Singhal (University of Pennsylvania, Philadelphia, PA, USA) to discuss intraoperative molecular imaging, with focus on its application in lung cancer. The presentation entitled ‘Intraoperative molecular imaging of lung cancer: The […]
Gerard Zalcman, ESMO 2022: IFCT-1701 phase III trial, investigating nivolumab plus ipilimumab in advanced non-small cell lung cancer
First-line immunotherapy is a standard treatment for patients with advanced non-small cell lung cancer. Prof. Gerard Zalcman (Bichat Hospital, Assistance Publique-Hôpitaux de Paris; Institute of Cancer AP-HP Nord, Paris, France) joins touchONCOLOGY to discuss the IFCT-1701 phase III trial, investigating nivolumab plus ipilimumab, aiming to assess if 6-months nivolumab/ipilimumab duration was equivalent to continuation until progression […]
Charles Swanton, ESMO 2022: Mechanism of action and an actionable inflammatory axis for air pollution may induce NSCLC in never-smokers
The mechanistic basis for non-small cell lung cancer (NSCLC) initiation in never smokers is unknown. The air pollutant, particulate matter, is known to be associated with the risk of NSCLC, however a direct cause and mechanism remains difficult to achieve. Prof. Charles Swanton (Francis Crick Institute, London, UK) joins touchONCOLOGY to discuss his study into […]
Journal articles and more to your inbox
Get the latest clinical insights from touchONCOLOGYSign me up!